内容紹介
Treatment of Cancer Chemotherapy-Associated Anemia in Japan―Conditions and Issues
Summary
Cancer chemotherapy-induced anemia(CIA)is observed in approximately 70% of patients treated with cytotoxic chemotherapy. The hemoglobin concentration in the peripheral blood is ≤10 g/dL in 40% of these patients, and ≤8 g/dL in 23% of these patients. Red blood cell transfusion is performed in 16% of these patients. Since erythropoiesis-stimulating agents(ESA)are not approved in Japan, blood transfusion is the only choice of treatment for CIA. In Northwestern countries, ESA have been utilized for the treatment of CIA for >20 years. Recently, however, the use of ESA has become regulated towing to concerns about the potential life-shortening effects, although ESA are still the treatment of choice for CIA. In this paper, the characteristics of CIA in Japan and the underlying issues have been discussed.
要旨
がん化学療法に伴う貧血(chemotherapy-induced anemia: CIA)は,化学療法を受けた患者の約70%に認められ,そのうち40%はヘモグロビン10 g/dL以下,23%は8 g/dL以下であり,輸血が16%の患者に行われている。造血刺激薬(erythropoiesis-stimulating agents: ESA)は本邦ではCIA治療薬として認可されていないため,輸血のみが積極的治療の唯一の選択肢である。欧米では20年前からESAがCIA治療に用いられているが,近年,潜在的な生存短縮効果が問題となり厳重な適正使用が必須とされている。本稿では本邦におけるCIA治療の現状と問題点について考察する。
目次
Summary
Cancer chemotherapy-induced anemia(CIA)is observed in approximately 70% of patients treated with cytotoxic chemotherapy. The hemoglobin concentration in the peripheral blood is ≤10 g/dL in 40% of these patients, and ≤8 g/dL in 23% of these patients. Red blood cell transfusion is performed in 16% of these patients. Since erythropoiesis-stimulating agents(ESA)are not approved in Japan, blood transfusion is the only choice of treatment for CIA. In Northwestern countries, ESA have been utilized for the treatment of CIA for >20 years. Recently, however, the use of ESA has become regulated towing to concerns about the potential life-shortening effects, although ESA are still the treatment of choice for CIA. In this paper, the characteristics of CIA in Japan and the underlying issues have been discussed.
要旨
がん化学療法に伴う貧血(chemotherapy-induced anemia: CIA)は,化学療法を受けた患者の約70%に認められ,そのうち40%はヘモグロビン10 g/dL以下,23%は8 g/dL以下であり,輸血が16%の患者に行われている。造血刺激薬(erythropoiesis-stimulating agents: ESA)は本邦ではCIA治療薬として認可されていないため,輸血のみが積極的治療の唯一の選択肢である。欧米では20年前からESAがCIA治療に用いられているが,近年,潜在的な生存短縮効果が問題となり厳重な適正使用が必須とされている。本稿では本邦におけるCIA治療の現状と問題点について考察する。